• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>British Journal of Cancer >Outcome in stage III non-Hodgkins lymphoma in children (UKCCSG study NHL 86)--how much treatment is needed? United Kingdom Childrens Cancer Study Group.
【2h】

Outcome in stage III non-Hodgkins lymphoma in children (UKCCSG study NHL 86)--how much treatment is needed? United Kingdom Childrens Cancer Study Group.

机译：儿童III期非霍奇金淋巴瘤的结果（UKCCSG研究NHL 86）-需要多少治疗？英国儿童癌症研究小组。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Forty-four children aged 3-13 years with Murphy stage III B cell non-Hodgkin's lymphoma were treated between May 1986 and December 1989. All have been followed up for at least 12 months. The primary site was the abdomen in 37 children, 24 of whom had involvement of other organs or nodal disease outside the abdomen. Twenty-eight received a standard dose regimen (regimen 1) and 16 had a more intensive regimen (regimen 2--MACHO). Fourteen patients (87%) who received MACHO had extensive multi-organ disease compared to 15 (53%) on regimen 1. Most of the latter had only pleural effusions. Thirty-four children are alive relapse free and considering the early relapse pattern in this disease are probably cured (actuarial event free survival = 76%). There has been one relapse (6%) after MACHO, but three toxic deaths. Six patients (21%) on the less intensive regimen have relapsed. Morbidity was high in terms of infection and need for haematological support and hospitalisation in the one third of children electively given the more intensive regimen. It is concluded that the vast majority of children with stage III disease who have disease limited to lymph nodes are curable with a moderately intensive regimen. Those with multiorgan involvement probably require more intensive treatment. It is therefore of importance to clarify prognostic factors in these patients to determine who can be cured with a less intensive regimen and who requires further dose intensification.
机译：在1986年5月至1989年12月之间对44例3-13岁的Murphy III B细胞非霍奇金淋巴瘤儿童进行了治疗。所有这些患者均已接受了至少12个月的随访。主要部位是腹部的37名儿童，其中24名患有其他器官或腹部以外的淋巴结疾病。 28个接受了标准剂量方案（方案1），而16个接受了更严格的方案（方案2-MACHO）。接受MACHO治疗的14例患者（87％）患有广泛的多器官疾病，而方案1则为15例（53％）。大多数后者只有胸腔积液。三十四名儿童没有复发，并且考虑到这种疾病的早期复发模式可能已经治愈（无精算事件存活率= 76％）。 MACHO发生后复发1次（6％），但有3例中毒死亡。强度较低的方案中有6例（21％）复发。在三分之一的儿童中，有较高的感染率，并且有较高的发病率，需要选择性的血液学支持和住院治疗。结论是，只有中度强化治疗才能治愈绝大多数患有淋巴结疾病的III期儿童。那些多器官受累者可能需要更深入的治疗。因此，重要的是要弄清楚这些患者的预后因素，以确定谁可以用较低强度的治疗方法治愈，以及谁需要进一步的剂量增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号